Healthcare
Livzon Pharmaceutical Group Inc.(LVZPF)
Live Price
Offline$5.22
+0.00% today
1Y Change
+52.19%
Window
Jun 25, 2025 โ Jun 22, 2026
- Market Cap
- $28.99B
- Revenue Growth
- -1.8%
- EPS Growth
- 0.0%
- Dividend Yield
- 3.4%
Coverage: 254 bars ยท Jun 25, 2025 โ Jun 22, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Livzon Pharmaceutical Group Inc. (LVZPF) is a Healthcare stock with a market cap of $28.99B and listed on OTC. The stock last traded around $5.22 and up 52.2% across the available one-year price window (Jun 25, 2025 โ Jun 22, 2026). Baseline metrics include revenue growth of -1.8%, EPS growth of 0.0%, a dividend yield of 3.4%. What stands out right now is revenue -1.8%, EPS 0.0%, free cash flow +5.4% with operating margin 22.7% and ROIC 11.4%. The dividend matters to the case here, with a current yield around 3.4%. Valuation is more restrained than many high-expectation growth names at P/E 14.8 and price/sales 2.5. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines LVZPF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-1.8% vs +7.6% peer median
Operating Margin
Above sector median
+22.7% vs +19.4% peer median
P/E
Below sector median
14.8 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 24, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -1.8% and EPS is at 0.0%, with operating margin around 22.7%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 3.4%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 24, 2026 | โ | +0.0% | +0.0% | +0.0% |
2026 Mar 24, 2026 | -18.9% | +0.0% | +0.0% | +0.0% |
2025 Apr 21, 2025 | +1.1% | +0.0% | +0.0% | +0.0% |
Benchmark Edge
LVZPF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
LVZPF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
LVZPF Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for LVZPF and SPY.
Company Overview
Livzon Pharmaceutical Group Inc.
Other OTC
Livzon Pharmaceutical Group Inc. engages in the research, development, production, and sale of pharmaceutical products, and active pharmaceutical ingredients and intermediates in the People's Republic of China. The company offers Ilaprazole enteric coated tablets for the treatment of duodenal ulcers and reflux esophagitis; Laprazole sodium for injection to treat peptic ulcer hemorrhage; Leuprorelin Acetate Microspheres for injection; Urofollitropin for injection to treat anovulation and sufferers; Perospirone Hydrochloride for the treatment of schizophrenia; Anti-viral Granules to treat upper respiratory tract infection and influenza; and Shenqi Fuzheng Injection for the treatment of weakness and tiredness, lassitude, spontaneous sweating, and vertigo, as well as for the patients of lung and stomach cancer. It also offers diagnostic reagents, such as diagnostic kit for IgM/IgG antibody to coronavirus; nucleic acid test kit for human immunodeficiency virus type 1; antinuclear antibody test kits; interferon-gamma release assays test kits; and rapid test for mycoplasma pneumoniae IgM antibody. In addition, the company provides biochemical drugs, microbiological preparations, biologic products, Chinese drug preparations and pharmaceutical raw materials, and antibiotics. It also exports its products. The company was founded in 1985 and is headquartered in Zhuhai, China.
- Leadership
- Daping Liu
- IPO Date
- Jun 29, 2018
- Employees
- 9.1k
- Street Address
- Headquarters Building
- Mailing
- Zhuhai, 519090
- Region
- Zhuhai, CN
- Reporting Currency
- USD
- Investor Line
- 86 75 6813 5888
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 14.8
- EV/EBITDA
- 8.3
- Price/Sales
- 2.5
- Price/Book
- 2.0
Growth
- Revenue
- -1.8%
- EPS
- 0.0%
- Free Cash Flow
- +5.4%
Profitability
- Gross Margin
- 65.7%
- Operating Margin
- 22.7%
- Net Margin
- 16.8%
- ROE
- 14.0%
- ROIC
- 11.4%
Balance Sheet
- Debt/Equity
- 0.26
- Current Ratio
- 1.96
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.